Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
A phase 3 trial of Cosibelimab, Cisplatin, Carboplatin and Pemetrexed in Non-small-cell lung cancer, run by Checkpoint Therapeutics, Inc., recorded as terminated on the registry.
Overview
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC is a phase 3 interventional study registered as NCT04786964 by Checkpoint Therapeutics, Inc., with 25 participants recorded, started 2021-12-08 and due to reach its primary completion in 2023-12-30. Interventions recorded: Cosibelimab, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4mg. Conditions recorded: Metastatic Non-squamous Non Small Cell Lung Cancer.
Linked to the drug Cosibelimab because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialLDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialTusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.